Akebia Therapeutics Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Akebia Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View analyst ratings for Akebia Therapeutics or view top-rated stocks.

Wall Street analysts have given Akebia Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Akebia Therapeutics.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings data on Wednesday, February, 24th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.20. Akebia Therapeutics had a negative net margin of 126.86% and a negative trailing twelve-month return on equity of 68.51%.
View Akebia Therapeutics' earnings history.

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKBA stock has decreased by 50.6% and is now trading at $3.43.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 12-month price targets for Akebia Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they expect Akebia Therapeutics' stock price to reach $10.29 in the next twelve months. This suggests a possible upside of 199.9% from the stock's current price.
View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts.

28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Akebia Therapeutics include ADC Therapeutics (ADCT), Seres Therapeutics (MCRB), NGM Biopharmaceuticals (NGM), Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL), Pandion Therapeutics (PAND), COMPASS Pathways (CMPS), Revance Therapeutics (RVNC), Organogenesis (ORGO), Shattuck Labs (STTK), Arcutis Biotherapeutics (ARQT), ImmunoGen (IMGN), Endo International (ENDP), Zymeworks (ZYME) and Zentalis Pharmaceuticals (ZNTL).
View all of AKBA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.89%), Satter Management CO. L.P. (3.22%), Northern Trust Corp (1.21%), Dimensional Fund Advisors LP (1.21%), Rice Hall James & Associates LLC (1.07%) and Renaissance Technologies LLC (1.00%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics.

AKBA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Squarepoint Ops LLC, BlackRock Inc., SG Americas Securities LLC, Engineers Gate Manager LP, Alliancebernstein L.P., Virginia Retirement Systems ET AL, and Dynamic Technology Lab Private Ltd. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, and Maxine Gowen.
View insider buying and selling activity for Akebia Therapeutics or view top insider-selling stocks.

AKBA stock was purchased by a variety of institutional investors in the last quarter, including Satter Management CO. L.P., Renaissance Technologies LLC, Principal Financial Group Inc., Nisa Investment Advisors LLC, Russell Investments Group Ltd., Tudor Investment Corp Et Al, Bank of New York Mellon Corp, and Virtus ETF Advisers LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics or or view top insider-buying stocks.

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKBA stock can currently be purchased for approximately $3.43.

Akebia Therapeutics has a market capitalization of $495.77 million and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

Akebia Therapeutics employs 358 workers across the globe.

The official website for Akebia Therapeutics is www.akebia.com.

Akebia Therapeutics is headquartered at 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]